Pearson Family Chair
Acting Chair, Committee on the Neurobiology of Addictive Disorders, Director, Laboratory of Clinical Psychopharmacology
Director, Pearson Center for Alcoholism and Addiction Research
Committee On The Neurobiology Of Addictive Disorders
Adjunct Professor, Department of Psychiatry, University of California, San Diego
Adjunct Professor, Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine
The focus of the research programs in Dr. Mason’s Laboratory of Clinical Psychopharmacology is the clinical evaluation of potential medications for protracted abstinence and relapse prevention in alcohol dependence and related disorders such as nicotine and cannabis dependence. Research projects range from proof-of-concept early phase human laboratory studies to long-term, double-blind, placebo-controlled clinical efficacy studies. A critical aspect of the conceptual framework under which the Laboratory of Clinical Psychopharmacology is predicated is the dynamic feedback from the research findings of pre-clinical and clinical studies, which are designed to streamline information and provide converging evidence for ultimate clinical use. The critical conceptual framework is that the pre-clinical animal studies will inform the clinical laboratory studies, and the clinical laboratory studies will in turn inform the pre-clinical animal studies to further refine basic research involving animal models and the neuropharmacological approach. This approach has identified neuropharmacological domains that are currently being translated into long-term clinical efficacy studies.
Dr. Mason conducted the seminal studies of nalmefene as a novel treatment for alcohol dependence; nalmefene (Selincro) has recently received regulatory approval for this indication throughout the European Union. Dr. Mason also served as overall Principal Investigator for the 21-site U.S. study of acamprosate for the treatment of alcohol dependence, conducted in support of FDA approval. Results from her studies of gabapentin for the treatment of alcohol dependence served as the basis for developing a pivotal trial of Horizant (gabapentin enacarbil) as a treatment for alcohol use disorder.
Future Research Plans
Future research will include human laboratory studies to rapidly screen potential relapse prevention medications and clinical trials to evaluate the safety and efficacy of novel medications to prevent relapse and reduce symptoms of protracted abstinence in outpatients with alcohol dependence or cannabis dependence.
Ph.D., Clinical Psychology, Long Island University, 1983
B.F.A., Bachelor of Fine Arts, Pratt Institute, 1972
2003-present Professor, Committee on the Neurobiology of Addictive Disorders (formerly the Molecular and Integrative Neurosciences Department, and the Department of Neuropharmacology), The Scripps Research Institute, La Jolla, CA
2003-present Director, Laboratory of Clinical Psychopharmacology, The Scripps Research Institute, La Jolla, CA
2003-present Co-Director to Director, Pearson Center for Alcoholism and Addiction Research, The Scripps Research Institute, La Jolla, CA
1991-2003 Associate Professor to Professor with Tenure, Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL
1993-2003 Director, Division of Substance Abuse, Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL
1990-1991 Chief, Alcohol Disorders Clinic, Department of Psychiatry, New York Hospital-Cornell University Medical Center, New York, New York
1981-1991 Research Associate to Assistant Professor of Psychology, Department of Psychiatry, Cornell University Medical College, New York, New York
1981-1984 Assistant Professor of Psychology, Long Island University, Brooklyn, New York
1980-1984 Psychology Intern, Roosevelt Hospital-St. Lukes Medical Center, New York, New York
National Institutes of Health (NIH): Member, National Advisory Council on Drug Abuse; 2012-2014
Weill Cornell Alumni Award; 2009
The Pearson Family Chair; an endowed chair in alcoholism and addiction research at The Scripps Research Institute; 2007-present
Elected Fellow; American College of Neuropsychopharmacology; 2005
MERIT Award for Medication Development; National Institutes of Health (NIH); 2003-2014
Dean’s Senior Clinical Research Award; Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine; 1999-2000
National Institute on Alcohol Abuse and Alcoholism (NIAAA): Member, National Advisory Council; 1998-2002
National Institute on Alcohol Abuse and Alcoholism (NIAAA): Member, Clinical and Treatment Subcommittee Initial Review Group; 1993-1997
Teacher-Scientist Award; Andrew W. Mellon Foundation, Cornell University Medical College; 1989-1991
Editorial Activities: served as field editor for Neuropharmacology and as a member of the editorial boards for the Journal of Addiction Medicine, Alcoholism: Clinical and Experimental Research, Journal of Substance Abuse, and the Ninth and Tenth Special Reports to the US Congress on Alcohol and Health from the Secretary of Health and Human Services.
International activities: invited lectures on alcoholism and drug addiction for governments, academic institutions, and professional societies in Europe, Asia, North and South America and Africa.
Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Internal Medicine; 2014; 174(1):70-77
Note: Results served as the basis for a pivotal trial of Horizant (gabapentin enacarbil) conducted in support of FDA approval as a new treatment for alcohol dependence.
Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffins K, Kyle M, Adusumalli M, Begovic A, Rao S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology; 2012; 37(7):1689-98
Note: This is the only positive treatment study for cannabis use and withdrawal.
Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcoholism: Clinical and Experimental Research; 2012; 36(3):497-508
Crean, R.D., Crane, N.A., Mason, B.J. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. Journal of Addiction Medicine; 2011; 5:1-8
Koob, G.F., Lloyd, G.K., Mason, B.J. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nature Reviews. Drug Discovery; 2009; 8:500-515
Mason, B.J., Light, J.M., Williams, L.D., Drobes, D.J. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addiction Biology; 2009; 14:73-83
Note: This paper is part of a special issue of Addiction Biology co-edited by Dr. Mason devoted to human laboratory approaches to addiction research.
Mason, B.J., Light, J.M., Escher, T., Drobes, D.J. Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology; 2008; 200:141-150
Mason, B.J., Goodman, A.M., Chabac, S., Lehert, P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. Journal of Psychiatric Research; 2006; 40:383-393
Note: This 21-site study was conducted in support of FDA approval for acamprosate (Campral) treatment of alcohol dependence. Dr. Mason served as overall PI and was instrumental in the design of the protocol and counseling materials, which are available at www.alcoholfree.info.
Mason, B.J., Goodman, A.M., Dixon, R.M., Abdel Hameed, M.H., Hulot, T., Wesnes, K., Hunter, J.A, Boyeson, M.G. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology; 2002; 27:596-606
Note: This was the first interaction study of these two new medications for alcohol dependence.
Mason, B.J., Salvato, F.R., Williams, L.D., Ritvo, E.C., Cutler, R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Archives of General Psychiatry; 1999; 56:719-724
Note: NIH chose this project for presentation by Dr. Varmus, Director of NIH, to the U.S. Congress as a pivotal study of 1999. Selincro (nalmefene) was approved as a new treatment for alcohol dependence throughout the European Union (2012).
Mason, B.J., Kocsis, J.H., Ritvo, E.C., Cutler, R.B. A double-blind, placebo-controlled trial of desipramine in primary alcohol dependence stratified on the presence or absence of major depression. Journal of the American Medical Association; 1996; 275:761-767
Note: This project was chosen by the American Medical Association (AMA) to be the lead article in JAMA and was the focus of an AMA media briefing. This work was described by Alan Gelenberg, M.D., in the Biological Therapies in Psychiatry Newsletter as “a landmark work of major public health significance.”